|
A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma Clinical research trials and A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma. A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma clinical trial. Human subjects frequently get the finest healthcare available for their A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma  A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma
A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma
For Condition: Sarcoma, Kaposi,HIV Infections
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: To evaluate the safety and toxicity of combination therapy for AIDS-associated Kaposi's sarcoma with zidovudine (AZT) and two kinds of interferon alpha. The two kinds are interferon alpha (IFN-A) and interferon alpha-2A (recombinant) (IFN-A2A). To define the pharmacokinetics of AZT and IFN-A or AZT and IFN-A2A when given in combination. To define the maximum tolerated dose (MTD) of each drug in combination and to define doses to be used in Phase II trial. AZT has been found to be effective against the effects of HIV in vitro (test tube) and both interferons have shown antiviral and antitumor effect on Kaposi's sarcoma. It is reasonable to assume that a synergism and an enhanced antitumor response may be seen with combination therapy. A study to evaluate the safety and effectiveness of AZT in the combination with IFN-A2A is warranted.
Details: AZT has been found to be effective against the effects of HIV in vitro (test tube) and both interferons have shown antiviral and antitumor effect on Kaposi's sarcoma. It is reasonable to assume that a synergism and an enhanced antitumor response may be seen with combination therapy. A study to evaluate the safety and effectiveness of AZT in the combination with IFN-A2A is warranted. Patients are randomized to receive IFN-A or IFN-A2A by intramuscular injection and combined with AZT orally daily for 8 weeks. Two cohorts of 4 patients enter each dose level. Patients do not enter into the next dose level until all patients have completed 3 weeks of treatment. AZT escalates only if there is no unacceptable toxicity (grade 2 in = or > 3 patients or > grade 2 in any patients); subsequent increase in IFN-A or IFN-A2A will be permitted, but the AZT dose will remain fixed. The MTD for a given IFN-A or IFN-A2A dose level is defined as grade 3 toxicity for hemoglobin or grade 2 toxicity for other parameters in 3 of the 6 patients. Once the MTD is reached, there will be no further enrollment at higher dose level. Patients are followed every week for vital signs and hematologic studies. Patients tolerating the combination may be continued on therapy for 1 year at the same dose as the end of 8th week.
Eligibility:
Study Type: Interventional, Treatment, Open Label
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria - Patient must have a histologically confirmed diagnosis of Kaposi's sarcoma. - Positive antibody to HIV confirmed by ELISA or Western blot on the same serum. Exclusion Criteria - Active drug or alcohol abuse. Co-existing Condition: Patients with the following complications are excluded: - Active opportunistic infections requiring ongoing therapy. - Pneumocystis carinii pneumonia (PCP) unless recovered must be off therapy within 90 days prior to study. - Clinically significant cardiac disease, including a history of myocardial infarction or arrhythmia. - Concurrent neoplasms other than basal cell carcinoma of skin. - Known sensitivity to polymycin or neomycin. Patients with the following complications are excluded: - Active opportunistic infections requiring ongoing therapy. - Pneumocystis carinii pneumonia (PCP) unless recovered must be off therapy within 90 days prior to study. - Clinically significant cardiac disease, including a history of myocardial infarction or arrhythmia. - Concurrent neoplasms other than basal cell carcinoma of skin. - Known sensitivity to polymycin or neomycin. Prior Medication: Excluded: - Any prior zidovudine (AZT) or interferon alpha protocol participation. - Excluded within 30 days of study entry: - Immunomodulating agents. - Other drugs that can cause neutropenia or significant nephrotoxicity, or systemic anti-infectives. - Excluded within 90 days of study entry: - Antiretroviral agents. - Treatment of Pneumocystis carinii pneumonia (PCP). Prior Treatment: Excluded within 30 days of study entry: - Radiation therapy.
Total Enrollment: 48
Location and Contact Information:
Overall Study Official:
KrownS, Study Chair,
Mem Sloan - Kettering Cancer Ctr
New York City, New York, 10021
United States
Additional Information:
Study ID Numbers: ACTG 014;
Study Start Date:
Record last reviewed: September 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001113
Other Sarcoma, Kaposi Studies:
1. SU5416 in Patients with AIDS-Related Kaposi's Sarcoma
2. A Study of ALRT 1057 Topical Gel in Patients with AIDS-Related Kaposi's Sarcoma
3. A Study of Tecogalan Sodium
4. KSHV Infection in Blood Donors from Texas
5. A Study of Doxorubicin in the Treatment of AIDS-Related Kaposi's Sarcoma
Related Studies:
Other Sarcoma, Kaposi Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma
|
|
|
|
|
|
|
|
